510(k) Report

510(k) · Cleared

Cleared

Cefaly Acute

K171446510(k) TraditionalCleared Sep 15, 2017122-day reviewClass II21 CFR 882.5891

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Cefaly Technology · PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine

Cleared on Sep 15, 2017 as substantially equivalent to K160237 (Cefaly Technology, 2016) after a 122-day review. Its family tree reaches back 2 generations to 2014. 13 later devices descend from it.

Decided
Sep 15, 2017
Review
122 days
Class
Class II
Product code
PCC
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN120019 (2014). 13 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2017: 1 descendant cleared2021: 4 descendants cleared2022: 1 descendant cleared2020: 1 descendant cleared2024: 5 descendants cleared2026: 1 descendant clearedDEN120019 · Cefaly · Stx-Med Sprl · 2014K160237 · Cefaly · Cefaly Technology · 20162010201520202025
Descendants, by generation 1 generation forward: 2 descendants2 generations forward: 4 descendants3 generations forward: 6 descendants4 generations forward: 1 descendant K160237 · Cefaly · Cefaly Technology · 2016DEN120019 · Cefaly · Stx-Med Sprl · 20140
  1. Root · 2 generations backDEN120019 CefalyStx-Med Sprl · 2014
  2. 1 generation backK160237 CefalyCefaly Technology · 2016
  3. This deviceK171446 Cefaly AcuteCefaly Technology · 2017
  4. Descendant · cites it directly · 10 of its ownK173006 Cefaly DualCefaly Technology · 2017
  5. Descendant · 2 generations on · 7 of its ownK201895 Cefaly DualCefaly Technology · 2020
  6. Descendant · 2 generations on · 2 of its ownK212071 Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID…Cefaly Technology · 2022
  7. Descendant · 3 generations on · 1 of its ownK234029 CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology · 2024
  8. Descendant · 2 generations on · 1 of its ownK211380 ElexirNu Eyne Co., Ltd. · 2021

Showing 5 of 13 descendants. See all descendants

Descendants cleared per year

2017: 12020: 12021: 42022: 12024: 52026: 1
2017high 5 (2024) · low 0 (2018)2026

Most influential descendants

Showing 5 of 13 · See all
  • K173006Cefaly DualCefaly Technology · 2017 · cites it directly10descendants
  • K201895Cefaly DualCefaly Technology · 2020 · 2 generations on7descendants
  • K212071Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx, Cefaly Dual…Cefaly Technology · 2022 · 2 generations on2descendants
  • K234029CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology · 2024 · 3 generations on1descendant
  • K211380ElexirNu Eyne Co., Ltd. · 2021 · 2 generations on1descendant
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN120019CefalyStx-Med Sprl2014—
−1K160237CefalyCefaly Technology2016—
0 (this device)K171446Cefaly AcuteCefaly Technology2017—
+1K173006Cefaly DualCefaly Technology2017—
+2K201895Cefaly DualCefaly Technology2020—
+2K212071Cefaly Dual Enhanced with RFID - OTC, Cefaly Dual Enhanced with RFID - Rx…Cefaly Technology2022—
+3K234029CEFALY Connected - OTC, CEFALY Connected - RxCefaly Technology2024—
+2K211380ElexirNu Eyne Co., Ltd.2021—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201710
202010
202140
202210
202450
202610
FIG. 1 — Lineage of K171446, 2014–2026Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in PCC? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new PCC device

  1. #1 K201895 Cefaly Dualscore 16.0 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K160237Cefaly
Summary page 4
…5.3. Substantial equivalency Substantial Equivalency is claimed against the following legally marketed device: Cefaly® (510(k) number K160237). 5.4. Description of the device The Cefaly® Acute device is a supraorbital transcutaneous e…
Cefaly Technology2016—

Also cleared against K160237: 3 other devices →

What descends from it? (13)

See all 13

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K173006Cefaly DualCefaly Technology201710
K203419RelivionNeurolief, Ltd.20211

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 3 years and passes through 2 companies; a new generation was cleared every 2.0 years on median.
  • None of the 2 ancestors has a recall.
  • Of its descendants, K173006 (Cefaly Technology, 2017) has gone furthest, with 10 descendants of its own.
  • 3 other devices also cite its predicate K160237.

How does its category compare?

All PCC devices

PCC Stimulator, Nerve, Electrical, Transcutaneous, For Migraine: FDA decisions, review times, recalls and adverse event reports over 20 years. 2017, this device’s year, is highlighted.

FDA decisions per year · PCC

5in 2024

2014: 12016: 12017: 22018: 12019: 12020: 12021: 42022: 12024: 52026 (partial year): 1
2007high 5 (2024) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · PCC

211in 2024

2021: 88 days median2024: 211 days median
2007high 211 (2024) · low 88 (2021)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · PCC

No recall names PCC since 2007.

Adverse event reports per year · PCC

2in 2025

2014: 22016: 22017: 22019: 22020: 12021: 72023: 22024: 62025: 2
2007high 7 (2021) · low 0 (2007)2025

MAUDE reports naming product code PCC, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20141—02
20150—00
20161—02
20172—02
20181—00
20191—02
20201—01
202148807
20221—00
20230—02
2024521106
20250—02
20261—0—

What is it indicated for?

Cefaly® Acute is indicated for the acute treatment of migraine with or without aura in patients 18 years of age or older.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K171446: Cefaly Acute.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K171446

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026